Journal
CELL STEM CELL
Volume 24, Issue 2, Pages 299-+Publisher
CELL PRESS
DOI: 10.1016/j.stem.2018.11.018
Keywords
-
Categories
Funding
- Functional Genomics Core of the Penn Diabetes Research Center (NIH) [P30 DK19525]
- Cox Medical Institute
- JPB Foundation
- NIH [R01-DK049780, R01-DK098542, K08-DK094968, F32DK116519]
- American Diabetes Association [1-18-PDF-132]
Ask authors/readers for more resources
Thiazolidinedione drugs (TZDs) target the transcriptional activity of peroxisome proliferator activated receptor gamma (PPAR gamma) to reverse insulin resistance in type 2 diabetes, but side effects limit their clinical use. Here, using human adipose stem cell-derived adipocytes, we demonstrate that SNPs were enriched at sites of patient-specific PPAR gamma binding, which correlated with the individual-specific effects of the TZD rosiglitazone (rosi) on gene expression. Rosi induction of ABCA1, which regulates cholesterol metabolism, was dependent upon SNP rs4743771, which modulated PPAR gamma binding by influencing the genomic occupancy of its cooperating factor, NFIA. Conversion of rs4743771 from the inactive SNP allele to the active one by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated editing rescued PPAR gamma binding and rosi induction of ABCA1 expression. Moreover, rs4743771 is a major determinant of undesired serum cholesterol increases in rosi-treated diabetics. These data highlight human genetic variation that impacts PPAR gamma genomic occupancy and patient responses to antidiabetic drugs, with implications for developing personalized therapies for metabolic disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available